Parenteral > General injections > SC:
120 µg per 0.2 mL in prefilled syringe ;
300 µg per 0.5 mL in prefilled syringe ;
480 µg per 0.8 mL in prefilled syringe ;
300 µg per mL in 1 mL vial ;
480 µg per 1.6 mL in 1.6 mL vial
Summary of evidence and Expert Committee recommendations
In 2015, as part of the comprehensive review of cancer medicines undertaken by the Expert Committee, filgrastim, a granulocyte colony stimulating factor, was added to the complementary list of the EML and EMLc for use in the following indications:
- primary prophylaxis in patients at high risk for developing febrile neutropenia associated with myelotoxic chemotherapy;
- secondary prophylaxis for patients who have experienced neutropenia following prior myelotoxic chemotherapy;
- to facilitate administration of dose dense chemotherapy regimens.
The relevant extract from TRS994 regarding the Expert Committee's consideration of G-CSF is attached.